Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 32
GLP-1 gastroparesis symptoms and the gaps
A 2026 systematic review found only 12 published case reports of GLP-1 gastroparesis. Here is what they showed, and what they cannot tell you.
GLP-1 drugs at longevity clinics
Longevity and aesthetic clinics prescribe semaglutide and tirzepatide off-label. Here is what the labels cover, and where the ageing evidence stops.
SS-31, MOTS-c, and Tesamorelin: Evidence
What the published research says about SS-31, MOTS-c, GHK-Cu, and tesamorelin when people consider adding them to a retatrutide regimen.
Peptide cycles per year: no number exists
Cycle lengths come from a few small trials. Cycle counts come from nowhere, because no study has tested repeating a peptide course across a year.
Tirzepatide, blood pressure, cholesterol
A SURMOUNT post hoc analysis scores tirzepatide on all three targets at once. Between 32% and 38% of participants hit every one. Composites read differently.
Traveling to UK with Peptides: The Rules
UK law sets clear documentation rules for controlled drugs like TRT, while CJC-1295 and ipamorelin sit in a separate, less defined space.
GLP-1 agonists: laryngeal side effects
A 2026 study found GLP-1 receptor agonists raised cough and voice disorder risk in obese adults.
Beyond weight loss: GLP-1 organ outcomes
A JACC editorial reframes GLP-1 drugs as cardiometabolic medicines. The SELECT, FLOW and SOUL trials, and the approved labels, already point that way.
Do GLP-1 drugs cause throat symptoms?
A 2026 Laryngoscope cohort ties GLP-1 drugs to cough, globus and voice change. Here is what an association study can and cannot show.
GLP-1 drugs as cardiometabolic medicines
A 2026 JACC editorial argues GLP-1 drugs are cardiometabolic medicines first. Here is what the trial evidence shows.
What Lilly's retatrutide lawsuits mean
Eli Lilly sued six US sellers of unapproved retatrutide on 12 August 2026. Here is what the cases mean if you bought a vial or are considering one.
Obesity-driven HFpEF: what the drugs do
A 2026 review maps obesity-driven HFpEF from mechanism to prescribing. Semaglutide and tirzepatide improved symptoms and exercise capacity, not survival.